Abstract
Chemotherapy remains the standard treatment for acute myeloid leukemia; however, the emergence of drug resistance is a major hurdle in the successful treatment of leukemia. The expression of multidrug resistance-associated protein 4 (MRP4) induces resistance in the adriamycin-resistant acute myeloid leukemia cell line, K562/ADR. The aim of this study was to investigate whether knockdown of MRP4 by lentivirus-mediated siRNA could improve the sensitivity of K562/ADR cells to adriamycin. Five lentivirus-mediated short hairpin RNAs (lv-shRNAs-MRP4) were designed to trigger the gene silencing RNA interference (RNAi) pathway. The efficiency of lentivirus-mediated siRNA infection into K562/ADR cells was determined using fluorescence microscopy to observe lentivirus-mediated GFP expression. MRP4 expression in infected K562/ADR cells was evaluated by real-time PCR and Western blot analysis. The MTS assay was used to measure cell viability and flow cytometry was used to measure apoptosis. The transfection efficiency of K562/ADR cells was over 80 percent. The gene silencing efficacy of lv-shRNA1-MRP4 was superior to the other constructs. Infection of K562/ADR cells with lv-shRNA1-MRP4 led to strong inhibition of MRP4 mRNA and protein expression. Combined treatment with lv-shRNA1-MRP4 and adriamycin decreased cell growth and increased apoptosis compared to treatment with lv-shRNA1-MRP4 or adriamycin alone. These data indicate that in K562/ADR cells MRP4 is involved in drug resistance mechanisms and that lentivirus-mediated knockdown of MRP4 may enhance sensitivity to adriamycin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Jäger W. Classical resistance mechanisms. Int J Clin Pharm Th, 2009, 47: 46–48
Modok S, Mellor H R, Chllaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol, 2006, 6: 350–354
Van Der Kolk D M, De Vries E G E, Muller M, et al. The role of drug efflux pumps in acute myeloid leukemia. Leukemia Lymphoma, 2002, 43: 685–701
Ravna A W, Sager G. Molecular model of the outward facing state of the human multidrug resistance protein 4 (MRP4/ABCC4). Bioorg Med Chem Lett, 2008, 18: 3481–3483
Russel F G M, Koenderink G B, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): A versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci, 2008, 29: 200–207
Murray D N, Smith J, Tanabe K, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther, 2005, 4: 547–553
Steinbach D, Wittig S, Cario G, et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood, 2003, 102: 4493–4498
Peng X X, Shi Z, Damaraju V L, et al. Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leukemia Res, 2008, 32: 799–809
Huynh T, Wälchli S, Sioud M. Transcriptional targeting of small interfering RNAs into cancer cells. Biochem Biophys Res Commun, 2006, 350: 854–859
Liao W, Ning G. Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA. Biochem Biophys Res Commun, 2006, 344: 478–483
Numnum T M, Makhija S, Lu B, et al. Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol, 2008, 108: 34–41
Jung C R, Yoo J S, Jang Y J, et al. Adenovirus-mediated transfer of sirna against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 2006, 43: 1042–1052
Cioca D P, Aoki Y, Kiyosawa K. RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther, 2003, 10: 125–133
Rubinson D A, Dillon C P, Kwiatkowski A V, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet, 2003, 33: 401–406
Brummelkamp T P, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296: 550–553
Federico M. Lentivirus Gene Engineering Protocols (Methods in Molecular Biology). New Jersey: Humana Press, 2003
Tiscornia G, Singer O, Verma I M. Production and purification of lentiviral vectors. Nat Protoc, 2006, 1: 241–245
Sena-Esteves M, Tebbets J C, Steffens S, et al. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods, 2004, 122: 131–139
Reiser J. Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther, 2000, 7: 910–913
Kim D H, Lee N Y, Sung W J, et al. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes. Acta Haematol, 2005, 114: 78–83
Mi Y, Xue Y, Yu W, et al. Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype. Leukemia Lymphoma, 2008, 49: 524–530
Koistinen P, Raty R, Itala M, et al. Long-term outcome of intensive chemotherapy for adults with de novo acute myeloid leukaemia (AML): The nationwide AML-92 study by the Finnish Leukaemia Group. Eur J Haematol, 2007, 78: 477–486
Kruh G D, Belinsky M G. The MRP family of drug efflux pumps. Oncogene, 2003, 22: 7537–7552
Yoshida M, Suzuki T, Komiya T, et al. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int J Cancer, 2001, 94: 432–437
Adachi M, Reid G, Schuetz J D. Therapeutic and biological importance of getting nucleotides out of cells: A case for the ABC transporters, MRP4 and 5. Adv Drug Deliver Rev, 2002, 54: 1333–1342
Wei X L, Ni H, Wang Q S, et al. Impact of STAT4 gene silencing on the expression profile of proteins in EL-4 cells. Chin Sci Bull, 2009, 54: 3265–3270
Tomari Y, Zamore P D. Perspective: Machines for RNAi. Gene Dev, 2005, 19: 517–529
Doi N, Zenno S, Ueda R, et al. Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors. Curr Biol Jan, 2003, 13: 41–46
Choung S, Kim Y J, Kim S, et al. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun, 2006, 342: 919–927
Andrew G, John A, Antigoni P, et al. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood, 2005, 105: 2510–2518
Cockrell A S, Kafri T. Gene delivery by lentivirus vectors. Mol Biotechnol, 2005, 105: 2510–2518
Sinn P L, Sauter S L, McCray Jr P B. Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther, 2005, 12: 1089–1098
Li M J, James K, Li S, et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, Anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther, 2005, 12: 900–909
Levine B L, Humeau L M, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA, 2006, 103: 17372–17377
Li M, Rossi J J. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol, 2005, 309: 261–272
Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia, 2009, 14: 3–9
Materna V, Liedert B, Thomale J, et al. Protection of platinum DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer, 2005, 115: 393–402
Materna V, Stege A, Surowiak P, et al. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun, 2006, 348: 153–157
Chen T, Deng C S. Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immu, 2008, 8: 1006–1011
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Liu, B., Zhao, L., Ma, H. et al. Knockdown of MRP4 by lentivirus-mediated siRNA improves sensitivity to adriamycin in adriamycin-resistant acute myeloid leukemia cells. Chin. Sci. Bull. 57, 90–97 (2012). https://doi.org/10.1007/s11434-011-4840-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-011-4840-1